Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Vulvar Neoplasms 1Vulvar Diseases 1Uterine Cervical Dysplasia 1Triple Negative Breast Neoplasms 1Papillomavirus Infections 1Neoplasm Metastasis 1Carcinoma in Situ 1Carcinoma 1

Interventions

pembrolizumab 104Specimen Handling 55Magnetic Resonance Spectroscopy 48Biopsy 46Nivolumab 41Paclitaxel 35Gemcitabine 30Radiosurgery 29Carboplatin 28Ipilimumab 22Cyclophosphamide 22Cisplatin 22trastuzumab deruxtecan 21Irinotecan 21Capecitabine 19Leucovorin 18Fulvestrant 18Cetuximab 18130-nm albumin-bound paclitaxel 18Pemetrexed 17Fluorouracil 17Docetaxel 17Bevacizumab 17Drug Therapy 16Taxes 15Oxaliplatin 15olaparib 14abemaciclib 14Radiotherapy 14Trastuzumab 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasm Metastasis × Meperidine × 1 year × Clear all
NCT05035407 2025-12-02

T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers

National Institutes of Health Clinical Center (CC)

Phase 1 Terminated
36 enrolled 7 charts
Breast

Carcinoma, Neoplasm Metastasis, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡